Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma

Cancer Medicine

Volumn 5, Issue 10, 2016, Pages 2678-2687

  Chen, Jiang ^a   Yu, Yaojun ^a   Ji, Tong ^a,b   Ma, Rui ^c   Chen, Mingming ^a   Li, Gaofeng ^b   Li, Feibo ^d   Ding, Qiong ^d   Kang, Qingsong ^d   Huang, Diyu ^a   Liang, Xiao ^a   Lin, Hui ^a   Cai, Xiujun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d Department of Special Diagnosis   (China)

Author keywords

Hepatocellular carcinoma; Keap1; Oxidative stress; phosphorylated Nrf2 (pNrf2); prognosis

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; TRANSCRIPTION FACTOR NRF2; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN;

ADOLESCENT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; SURVIVAL TIME; TUMOR MULTIPLICITY; TUMOR VOLUME; ADULT; CELL NUCLEUS; CYTOPLASM; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATECTOMY; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LIVER NEOPLASMS; MALE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; PHOSPHORYLATION; PROGNOSIS; YOUNG ADULT;

EID: 84988353997     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.788     Document Type: Article

References (36)

1. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69–90.
2. Coleman, M., D. Forman, H. Bryant, J. Butler, B. Rachet, C. Maringe, et al. 2011. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. The Lancet 377:127–138.
3. Llovet, J. M., S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, et al. 2008. Sorafenib in advanced hepatocellular carcinoma. New England J. Med. 359:378–390.
4. Cheng, A. L., Y. K. Kang, Z. Chen, C. J. Tsao, S. Qin, J. S. Kim, et al. 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
5. Patel, T., and D. Harnois. 2014. Assessment of response to therapy in hepatocellular carcinoma. Ann. Med. 46:130–137.
6. Zhou, L., Y. Yang, D. Tian, and Y. Wang. 2013. Oxidative stress-induced 1, N6-ethenodeoxyadenosine adduct formation contributes to hepatocarcinogenesis. Oncol. Rep. 29:875–884.
7. Sporn, M. B., and K. T. Liby. 2012. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12:564–571.
8. Kawasaki, Y., S. Ishigami, T. Arigami, Y. Uenosono, S. Yanagita, Y. Uchikado, et al. 2015. Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer. BMC Cancer 15:5.
9. Jaramillo, M. C., and D. D. Zhang. 2013. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27:2179–2191.
10. Huang, C. F., L. Zhang, S. R. Ma, Z. L. Zhao, W. M. Wang, K. F. He, et al. 2013. Clinical significance of Keap1 and Nrf2 in oral squamous cell carcinoma. PLoS ONE 8:e83479.
11. Solis, L. M., C. Behrens, W. Dong, M. Suraokar, N. C. Ozburn, C. A. Moran, et al. 2010. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin. Cancer Res. 16:3743–3753.
12. Zhang, M. X., C. Zhang, L. M. Zhang, Q. Yang, S. N. Zhou, Q. S. Wen, et al. 2015. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer 15:531.
13. Yuan, Z., Q. Zheng, J. Fan, K. X. Ai, J. Chen, and X. Y. Huang. 2010. Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 136:1489–1496.
14. Yamaoka, H., K. Ohtsu, T. Sueda, T. Yokoyama, and E. Hiyama. 2006. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol. Rep. 15:551–556.
15. Lee, H. J., J. E. Yeon, S. J. Suh, S. J. Lee, E. L. Yoon, K. Kang, et al. 2014. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut. Liv. 8:177.
16. Niture, S. K., R. Khatri, and A. K. Jaiswal. 2014. Regulation of Nrf2-an update. Free Radic. Biol. Med. 66:36–44.
17. Schulze, K., S. Imbeaud, E. Letouze, L. B. Alexandrov, J. Calderaro, S. Rebouissou, et al. 2015. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47:505–511.
18. Taguchi, K., I. Hirano, T. Itoh, M. Tanaka, A. Miyajima, A. Suzuki, et al. 2014. Nrf2 enhances cholangiocyte expansion in Pten-deficient livers. Mol. Cell. Biol. 34:900–913.
19. Zou, Y. H., M. Hu, J. Lee, S. M. Nambiar, V. Garcia, Q. Bao, et al. 2015. Nrf2 is essential for timely M phase entry of replicating hepatocytes during liver regeneration. Am. J. Physiol-Gastrointest. Liver Physiol. 308:G262–G268.
20. Itoh, K., P. Ye, T. Matsumiya, K. Tanji, and T. Ozaki. 2015. Emerging functional cross-talk between the Keap1-Nrf2 system and mitochondria. J. Clin. Biochem. Nutr. 56:91–97.
21. Lewis, K. N., E. Wason, Y. H. Edrey, D. M. Kristan, E. Nevo, and R. Buffenstein. 2015. Regulation of Nrf2 signaling and longevity in naturally long-lived rodents. Proc. Natl. Acad. Sci. U S A. 112:3722–3727.
22. Yin, S., and W. Cao. 2015. Toll-Like receptor signaling induces Nrf2 pathway activation through p62-triggered Keap1 degradation. Mol. Cell. Biol. 35:2673–2683.
23. Hua, K. T., M. H. Chien, W. J. Lee, F. K. Hsieh, C. F. Li, T. Y. Cheng, et al. 2015. Keap1-Nrf2 interaction suppresses cell motility in lung adenocarcinomas by targeting the S100P protein. Clin. Cancer Res. 21:4719–4732.
24. Isohookana, J., K. M. Haapasaari, Y. Soini, and P. Karihtala. 2015. Keap1 expression has independent prognostic value in pancreatic adenocarcinomas. Diagn. Pathol. 10:28.
25. Rada, P., A. I. Rojo, S. Chowdhry, M. McMahon, J. D. Hayes, and A. Cuadrado. 2011. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 31:1121–1133.
26. Chowdhry, S., Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, and J. D. Hayes. 2013. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32:3765–3781.
27. Totoki, Y., K. Tatsuno, K. R. Covington, H. Ueda, C. J. Creighton, M. Kato, et al. 2014. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46:1267–1273.
28. Zavattari, P., A. Perra, S. Menegon, M. A. Kowalik, A. Petrelli, M. M. Angioni, et al. 2015. Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology 62:851–862.
29. Nault, J. C., J. Calderaro, L. Di Tommaso, C. Balabaud, E. S. Zafrani, P. Bioulac-Sage, et al. 2014. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60:1983–1992.
30. Nault, J. C., S. Rebouissou, and J. Zucman Rossi. 2015. NRF2/KEAP1 and Wnt/beta-catenin in the multistep process of liver carcinogenesis in humans and rats. Hepatology 62:677–679.
31. Yoo, N. J., H. R. Kim, Y. R. Kim, C. H. An, and S. H. Lee. 2012. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 60:943–952.
32. Cleary, S. P., W. R. Jeck, X. Zhao, K. Chen, S. R. Selitsky, G. L. Savich, et al. 2013. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58:1693–1702.
33. MacLeod, A. K., M. McMahon, S. M. Plummer, L. G. Higgins, T. M. Penning, K. Igarashi, et al. 2009. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 30:1571–1580.
34. Agyeman, A. S., R. Chaerkady, P. G. Shaw, N. E. Davidson, K. Visvanathan, A. Pandey, et al. 2012. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res. Treat. 132:175–187.
35. Matkowskyj, K. A., H. Bai, J. Liao, W. Zhang, H. Li, S. Rao, et al. 2014. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions. Hum. Pathol. 45:834–843.
36. Hayes, J. D., and A. T. Dinkova-Kostova. 2014. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 39:199–218.